Immunology and Clinical Manifestations of Non-Clonal Mast Cell Activation Syndrome

[1]  J. Celestin,et al.  Mast Cell Activation Syndrome: A Review , 2013, Current Allergy and Asthma Reports.

[2]  A. Órfão,et al.  Mast cell-related disorders presenting with Kounis syndrome. , 2012, International journal of cardiology.

[3]  P. Bonadonna,et al.  Drug allergy in mast cell disease , 2012, Current opinion in allergy and clinical immunology.

[4]  D. Jackson,et al.  Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  K. Sotlar,et al.  Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology , 2012, International Archives of Allergy and Immunology.

[6]  L. Afrin.  Sclerosing mediastinitis and mast cell activation syndrome. , 2012, Pathology, research and practice.

[7]  M. Triggiani,et al.  Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal , 2011, International Archives of Allergy and Immunology.

[8]  D. Metcalfe,et al.  Diagnosis and Treatment of Cutaneous Mastocytosis in Children , 2011, American journal of clinical dermatology.

[9]  J. Hornick,et al.  Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. , 2011, The Journal of allergy and clinical immunology.

[10]  L. Afrin.  Polycythemia from mast cell activation syndrome: lessons learned. , 2011, The American journal of the medical sciences.

[11]  L. Afrin.  Burning mouth syndrome and mast cell activation disorder. , 2011, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[12]  L. Afrin,et al.  Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options , 2011, Journal of hematology & oncology.

[13]  W. Egner,et al.  Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assay , 2011, Clinical and experimental immunology.

[14]  P. Valent,et al.  Mast cell activation syndrome: Proposed diagnostic criteria. , 2010, The Journal of allergy and clinical immunology.

[15]  T. Frieling,et al.  Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects , 2010, Immunogenetics.

[16]  A. Órfão,et al.  Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. , 2010, The Journal of allergy and clinical immunology.

[17]  L. Thomas,et al.  Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. , 2010, The Journal of investigative dermatology.

[18]  C. Akin.  Anaphylaxis and Mast Cell Disease: What Is the Risk? , 2010, Current allergy and asthma reports.

[19]  J. Douglass,et al.  Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient , 2009, Allergy.

[20]  L. Antonicelli,et al.  Mast cell diseases and the severity and course of intraoperative anaphylaxis. , 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[21]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[22]  J. Butterfield,et al.  Prevention of Mast Cell Activation Disorder-Associated Clinical Sequelae of Excessive Prostaglandin D2 Production , 2008, International Archives of Allergy and Immunology.

[23]  M. Tsai,et al.  Immunomodulatory mast cells: negative, as well as positive, regulators of immunity , 2008, Nature Reviews Immunology.

[24]  J. Ring,et al.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients , 2008, Allergy.

[25]  A. Koterba,et al.  Elevated Baseline Tryptase Levels in Patients with Mast Cell Activation Syndromes without Evidence of Mastocytosis , 2008 .

[26]  D. Metcalfe,et al.  The mast cell and allergic diseases: role in pathogenesis and implications for therapy , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[27]  J. Hornick,et al.  Immunoreactivity for CD25 in Gastrointestinal Mucosal Mast Cells is Specific for Systemic Mastocytosis , 2007, The American journal of surgical pathology.

[28]  L. Scott,et al.  Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. , 2007, Blood.

[29]  D. Metcalfe,et al.  Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. , 2007, The Journal of allergy and clinical immunology.

[30]  P. Conti,et al.  Differential release of mast cell mediators and the pathogenesis of inflammation , 2007, Immunological reviews.

[31]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[32]  N. Novak,et al.  Histamine and histamine intolerance. , 2007, The American journal of clinical nutrition.

[33]  M. Brüss,et al.  Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder , 2007, Scandinavian journal of gastroenterology.

[34]  P. Valent,et al.  Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome , 2006, International Archives of Allergy and Immunology.

[35]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[36]  C. Akin.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. , 2006, The Journal of molecular diagnostics : JMD.

[37]  M. Castells.  Mast cell mediators in allergic inflammation and mastocytosis. , 2006, Immunology and allergy clinics of North America.

[38]  朱丽琳,et al.  Anaphylaxis , 2006 .

[39]  J. Rivera,et al.  Molecular regulation of mast cell activation. , 2006, The Journal of allergy and clinical immunology.

[40]  Christine Tkaczyk,et al.  Integrated signalling pathways for mast-cell activation , 2006, Nature Reviews Immunology.

[41]  S. Raj,et al.  Hyperadrenergic Postural Tachycardia Syndrome in Mast Cell Activation Disorders , 2005, Hypertension.

[42]  Richard A Flavell,et al.  Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. , 2004, The Journal of allergy and clinical immunology.

[43]  A. Órfão,et al.  Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA) , 2004, Cytometry. Part B, Clinical cytometry.

[44]  D. Metcalfe,et al.  Activation of human mast cells by aggregated IgG through FcgammaRI: additive effects of C3a. , 2004, Clinical immunology.

[45]  K. Kandere-Grzybowska,et al.  IL-1 Induces Vesicular Secretion of IL-6 without Degranulation from Human Mast Cells1 , 2003, The Journal of Immunology.

[46]  J. Pléau,et al.  Toll‐like receptor 2 (TLR2) and TLR4 differentially activate human mast cells , 2003, European journal of immunology.

[47]  H. Katz.  Inhibitory receptors and allergy. , 2002, Current opinion in immunology.

[48]  K. Austen,et al.  Mastocytosis: Mediator-Related Signs and Symptoms , 2002, International Archives of Allergy and Immunology.

[49]  F. Re,et al.  Toll-like Receptor 2 (TLR2) and TLR4 Differentially Activate Human Dendritic Cells* , 2001, The Journal of Biological Chemistry.

[50]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[51]  A. Órfão,et al.  Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. , 2001, Leukemia research.

[52]  L. Schwartz.  Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. , 2001, Leukemia research.

[53]  M. Lacouture,et al.  gp49B1-αvβ3 interaction inhibits antigen-induced mast cell activation , 2001, Nature Immunology.

[54]  D. Metcalfe,et al.  Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis , 1998, Cancer.

[55]  L. Schwartz,et al.  Markers of mast cell degranulation. , 1997, Methods.

[56]  M. Brown,et al.  Cutting the cord: is birth already too late for primary prevention of allergy? , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[57]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Galli,et al.  Piecemeal degranulation of mast cells in the inflammatory eyelid lesions of interleukin-4 transgenic mice. Evidence of mast cell histamine release in vivo by diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. , 1994, Blood.

[59]  J. Morrow,et al.  Detection of the major urinary metabolite of prostaglandin D2 in the circulation: demonstration of elevated levels in patients with disorders of systemic mast cell activation. , 1994, The Journal of allergy and clinical immunology.

[60]  M. Frieri,et al.  Acute nonlymphocytic leukemia in systemic mastocytosis with biclonal gammopathy. , 1992, The Journal of allergy and clinical immunology.

[61]  N. Weidner,et al.  Mast-cell phenotype in indolent forms of mastocytosis. Ultrastructural features, fluorescence detection of avidin binding, and immunofluorescent determination of chymase, tryptase, and carboxypeptidase. , 1992, The American journal of pathology.

[62]  J. Oates,et al.  Biochemical diagnosis of systemic mast cell disorders. , 1991, The Journal of investigative dermatology.

[63]  M. Frieri,et al.  Lymphadenopathic mastocytosis with eosinophilia and biclonal gammopathy. , 1990, The Journal of allergy and clinical immunology.

[64]  W. Lorenz,et al.  Determination of histamine in human plasma: the European external quality control study 1988 , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[65]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[66]  E. R. Mcfadden,et al.  Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. , 1985, The Journal of allergy and clinical immunology.

[67]  L. Afrin.  Mast cell activation syndrome masquerading as agranulocytosis. , 2012, Military medicine.

[68]  F. Kratz,et al.  Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. , 2011, Internal medicine.

[69]  A. Dvorak.  Piecemeal degranulation of basophils and mast cells is effected by vesicular transport of stored secretory granule contents. , 2005, Chemical immunology and allergy.

[70]  D. Metcalfe,et al.  Differential diagnosis of the patient with unexplained flushing/anaphylaxis. , 2000, Allergy and asthma proceedings.

[71]  Z. Cohen,et al.  Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. , 1992, International archives of allergy and immunology.

[72]  F. B. Cerra.  Manual of Critical Care , 1987 .

[73]  D. Alling,et al.  Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Results of a double-blind clinical trial. , 1985, The American journal of medicine.